Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Guan, Xiao ^a   Zhang, Ning ^a   Yin, Yongshuo ^b   Kong, Beihua ^a   Yang, Qifeng ^a   Han, Zhiyan ^c   Yang, Xingsheng ^a  

^a SHANDONG UNIVERSITY   (China)

^b DONGGUAN PEOPLE'S HOSPITAL   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

Ovarian cancer; p63; p73; Polymorphism; Single nucleotide polymorphisms

Indexed keywords

ESTROGEN RECEPTOR; PROTEIN P63; PROTEIN P73;

ADULT; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; OVARY CANCER; PATHOLOGY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ALLELES; DISEASE SUSCEPTIBILITY; DNA-BINDING PROTEINS; FEMALE; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; MEMBRANE PROTEINS; MIDDLE AGED; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84867681487     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-89     Document Type: Article

References (38)

1. Clinical analysis for death in gynecological patients. Hu J, Zhu LR, Liao QP, Beijing Da Xue Xue Bao 2010 42 155 158 20396355
2. p73, a sophisticated p53 family member in the cancer world. Ozaki T, Nakagawara A, Cancer Sci 2005 96 729 737 10.1111/j.1349-7006.2005.00116.x 16271066 (Pubitemid 43019823)
3. The future of genetic studies of complex human diseases. Risch N, Merikangas K, Science 1996 273 1516 1517 10.1126/science.273.5281.1516 8801636 (Pubitemid 26301653)
4. SNPs in cancer research and treatment. Erichsen HC, Chanock SJ, Br J Cancer 2004 90 747 751 10.1038/sj.bjc.6601574 14970847 (Pubitemid 38406580)
5. p73 induces apoptosis via PUMA transactivation and Bax mitochondrial translocation. Melino G, Bernassola F, Ranalli M, Yee K, Zong WX, Corazzari M, Knight RA, Green DR, Thompson C, Vousden KH, J Biol Chem 2004 279 8076 8083 14634023 (Pubitemid 38294697)
6. ΔNp63α expression is regulated by the phosphoinositide 3-Kinase pathway. Barbieri CE, Barton CE, Pietenpol JA, J Biol Chem 2003 278 51408 51414 10.1074/jbc.M309943200 14555649 (Pubitemid 38020380)
7. Evolution of functions within the p53/p63/p73 family. De Laurenzi V, Melino G, Ann N Y Acad Sci 2000 926 90 100 11193045 (Pubitemid 32050146)
8. An antiapoptotic role for the p53 family member, p73, during developmental neuron death. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD, Science 2000 289 304 306 10.1126/science.289.5477.304 10894779 (Pubitemid 30469909)
9. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases. Barlev NA, Liu L, Chehab NH, Mansfield K, Harris KG, Halazonetis TD, Berger SL, Mol Cell 2001 8 1243 1254 10.1016/S1097-2765(01)00414-2 11779500 (Pubitemid 34084996)
10. Genome-wide association studies in aging-related processes such as diabetes mellitus, atherosclerosis and cancer. Kronenberg F, Exp Gerontol 2008 43 39 43 10.1016/j.exger.2007.09.005 17967522 (Pubitemid 350235151)
11. Regulation of female reproduction by p53 and its family members. Feng Z, Zhang C, Kang HJ, Sun Y, Wang H, Naqvi A, Frank AK, Rosenwaks Z, Murphy ME, Levine AJ, Hu W, FASEB J 2011 25 2245 2255 10.1096/fj.10-180166 21402718
12. Hippeläinen M, Infertility and risk of cancer. Duodecim 2012 128 851 857
13. Endometriosis, in vitro fertilisation and the risk of gynaecologicalmalignancies, including ovarian and breast cancer. Vlahos NF, Economopoulos KP, Fotiou S, Best Pract Res Clin Obstet Gynaecol 2010 24 39 50 10.1016/j.bpobgyn.2009.08.004 19733123
14. Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. Goode EL, Fridley BL, Vierkant RA, Cunningham JM, Phelan CM, Anderson S, Rider DN, White KL, Pankratz VS, Song H, Hogdall E, Kjaer SK, Whittemore AS, DiCioccio R, Ramus SJ, Gayther SA, Schildkraut JM, Pharaoh PP, Sellers TA, Cancer Epidemiol Biomarkers Prev 2009 18 935 944 10.1158/1055-9965.EPI-08-0860 19258477
15. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Notaridou M, Quaye L, Dafou D, Jones C, Song H, Høgdall E, Kjaer SK, Christensen L, Høgdall C, Blaakaer J, McGuire V, Wu AH, Van Den Berg DJ, Pike MC, Gentry-Maharaj A, Wozniak E, Sher T, Jacobs IJ, Tyrer J, Schildkraut JM, Moorman PG, Iversen ES, Jakubowska A, Mȩdrek K, Lubiński J, Ness RB, Moysich KB, Lurie G, Wilkens LR, Carney ME, et al. Int J Cancer 2011 128 2063 2074 10.1002/ijc.25554 20635389
16. Structure-function Of the tumor suppressor BRCA1. Clark SL, Rodriguez AM, Snyder RR, Hankins GD, Boehning D, Comput Struct Biotechnol J 2012 1 1 1 16
17. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Song H, Ramus SJ, Tyrer J, Bolton KL, Gentry-Maharaj A, Wozniak E, Anton-Culver H, Chang-Claude J, Cramer DW, DiCioccio R, Dörk T, Goode EL, Goodman MT, Schildkraut JM, Sellers T, Baglietto L, Beckmann MW, Beesley J, Blaakaer J, Carney ME, Chanock S, Chen Z, Cunningham JM, Dicks E, Doherty JA, Dürst M, Ekici AB, Fenstermacher D, Fridley BL, Giles G, Nat Genet 2009 41 996 1000 10.1038/ng.424 19648919
18. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Goode EL, Chenevix-Trench G, Song H, Ramus SJ, Notaridou M, Lawrenson K, Vierkant RA, Larson MC, Kjaer SK, Birrer MJ, Berchuck A, Schildkraut J, Tomlinson I, Kiemeney LA, Cook LS, Gronwald J, Garcia-Closas M, Gore ME, Campbell I, Whittemore AS, Sutphen R, Phelan C, Anton-Culver H, Pearce CL, Lambrechts D, Rossing MA, Chang-Claude J, Moysich KB, Goodman MT, Dörk T, Nat Genet 2010 42 874 879 10.1038/ng.668 20852632
19. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Raimondi S, Johansson H, Maisonneuve P, Gandini S, Carcinogenesis 2009 30 1170 1180 10.1093/carcin/bgp103 19403841
20. Polymorphisms in the vitamin D receptor and risk of ovarian cancer in four studies. Tworoger SS, Gates MA, Lee IM, Buring JE, Titus-Ernstoff L, Cramer D, Hankinson SE, Cancer Res 2009 69 1885 1891 10.1158/0008-5472.CAN-08-3515 19223536
21. p63 protects the female germ line during meiotic arrest. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis AH, Zhu Z, Elvin JA, Bronson RT, Crum CP, McKeon F, Nature 2006 444 624 628 10.1038/nature05337 17122775 (Pubitemid 44864440)
22. Differential expression of p63 isoforms in female reproductive organs. Kurita T, Cunha GR, Robboy SJ, Mills AA, Medina RT, Mech Dev 2005 122 1043 1055 10.1016/j.mod.2005.04.008 15922574 (Pubitemid 41080028)
23. Haplotype structure and selection of the MDM2 oncogene in humans. Atwal GS, Bond GL, Metsuyanim S, Papa M, Friedman E, Distelman-Menachem T, Ben Asher E, Lancet D, Ross DA, Sninsky J, White TJ, Levine AJ, Yarden R, Proc Natl Acad Sci U S A 2007 104 4524 4529 10.1073/pnas.0610998104 17360557 (Pubitemid 47186258)
24. Altered tumor formation and evolutionary selection of genetic variants in the human MDM4 oncogene. Atwal GS, Kirchhoff T, Bond EE, Montagna M, Menin C, Bertorelle R, Scaini MC, Bartel F, Böhnke A, Pempe C, Gradhand E, Hauptmann S, Offit K, Levine AJ, Bond GL, Proc Natl Acad Sci U S A 2009 106 10236 10241 10.1073/pnas.0901298106 19497887
25. Regulation of Fertility by the p53 Family Members. Hu W, Zheng T, Wang J, Genes Cancer 2011 2 420 430 10.1177/1947601911408892 21779510
26. Endometriosis, in vitro fertilisation and the risk of gynaecological malignancies, including ovarian and breast cancer. Vlahos NF, Economopoulos KP, Fotiou S, Best Pract Res Clin Obstet Gynaecol 2010 24 39 50 10.1016/j.bpobgyn. 2009.08.004 19733123
27. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. IeM S, Kurman RJ, Am J Pathol 2004 164 1511 1518 10.1016/S0002-9440(10)63708-X 15111296 (Pubitemid 38529752)
28. Mutations of BRAF and KRAS precede the development of ovarian serous borderline tumors. Ho CL, Kurman RJ, Dehari R, Wang TL, Shih IM, Cancer Res 2004 64 6915 6918 10.1158/0008-5472.CAN-04-2067 15466181 (Pubitemid 39330999)
29. High-Resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications. Gorringe KL, Jacobs S, Thompson ER, Sridhar A, Qiu W, Choong DY, Campbell IG, Clin Cancer Res 2007 13 4731 4739 10.1158/1078-0432.CCR-07-0502 17699850 (Pubitemid 47294779)
30. Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns inmucinous ovarian and appendiceal carcinomas. Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC, Clin Cancer Res 2005 11 7651 7657 10.1158/1078-0432.CCR-05-1008 16278384 (Pubitemid 41611606)
31. Targeting SRC in mucinous ovarian carcinoma. Matsuo K, Nishimura M, Bottsford-Miller JN, Huang J, Komurov K, Armaiz-Pena GN, Shahzad MM, Stone RL, Roh JW, Sanguino AM, Lu C, Im DD, Rosenshien NB, Sakakibara A, Nagano T, Yamasaki M, Enomoto T, Kimura T, Ram PT, Schmeler KM, Gallick GE, Wong KK, Frumovitz M, Sood AK, Clin Cancer Res 2011 17 5367 5378 10.1158/1078-0432.CCR- 10-3176 21737505
32. Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a Gynecologic Oncology Group study. Zaino RJ, Brady MF, Lele SM, Michael H, Greer B, Bookman MA, Cancer 2011 117 554 562 10.1002/cncr.25460 20862744
33. Gynecologic Cancer InterGroup: Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A, Int J Gynecol Cancer 2010 20 945 952 10.1111/IGC.0b013e3181dd0110 20683400
34. Expression of p73 and c-Abl proteins in human ovarian carcinomas. Niyazi M, Ghazizadeh M, Konishi H, Kawanami O, Sugisaki Y, Araki T, Nippon Med Sch 2003 70 234 242 10.1272/jnms.70.234 (Pubitemid 36829917)
35. Hormonal interactions in ovarian cancer. Emons G, Kavanagh JJ, Hematol Oncol Clin North Am 1999 13 145 161 10.1016/S0889-8588(05)70158-1 10080074 (Pubitemid 29104712)
36. Progesterone facilitates cisplatin toxicity in epithelial ovarian cancer cells and xenografts. Murdoch WJ, Van Kirk EA, Isaak DD, Shen Y, Gynecol Onco 2008 110 251 255 10.1016/j.ygyno.2008.03.021
37. Hormone therapy and ovarian cancer. Mørch LS, Løkkegaard E, Andreasen AH, Krüger-Kjaer S, Lidegaard O, JAMA 2009 302 298 305 10.1001/jama.2009.1052 19602689
38. Ovarian cancer and hormone replacement therapy in the Million Women Study. Beral V, Bull D, Green J, Reeves G, Million Women Study Collaborators, Lancet 2007 369 1703 1710 10.1016/S0140-6736(07)60534-0 17512855 (Pubitemid 46755369)